Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 1:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Graft Rejection Clear all
Not listed No phase listed Observational Accepts healthy volunteers

Assessing AlloSure Dd-cfDNA Monitoring Insights of Renal Allografts With Longitudinal Surveillance

NCT04566055
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
AlloSure
Device
Lead sponsor
CareDx
Industry
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
8
States / cities
Aurora, Colorado • Tampa, Florida • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Sep 22, 2026, 1:58 AM EDT
Recruiting Phase 1 Interventional

Treatment of Antibody-Mediated Rejection (ABMR) With CarBel

NCT06918990
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Carfilzomib, Belatacept
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
11
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 22, 2026, 1:58 AM EDT
Withdrawn No phase listed Observational

Study Correlation Between Blood, Tissue Gene Expression, Donor Derived Cell Free DNA and Histopathology in Kidney Transplant Recipients

NCT05811468
View directory record Official record
Conditions
Transplant;Failure,Kidney, Kidney Transplant, Kidney Rejection Transplant
Interventions
Not listed
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 100 Years
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Sep 22, 2026, 1:58 AM EDT
Enrolling by invitation Phase 2 Interventional

Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

NCT06126380
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
AT-1501, Tacrolimus
Drug
Lead sponsor
Eledon Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
26
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 22, 2026, 1:58 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor

NCT03707262
View directory record Official record
Conditions
Renal Transplant Rejection, Tolerance, Kidney Transplant
Interventions
Donor CD34+ and CD3+ cells
Biological
Lead sponsor
Jeffrey Veale, MD
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 22, 2026, 1:58 AM EDT
Completed No phase listed Observational

The TOGETHER Project - Kidney RNA-seq Validation

NCT03874299
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 18, 2022 · Synced Sep 22, 2026, 1:58 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection

NCT00300274
View directory record Official record
Conditions
Graft Rejection
Interventions
everolimus, mycophenolate mofetil, cyclosporine, corticosteroids
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
721 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
26
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2012 · Synced Sep 22, 2026, 1:58 AM EDT
Completed Phase 2 Interventional Results available

Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies

NCT00307125
View directory record Official record
Conditions
Kidney Transplant, Kidney Transplant Recipient, Graft Function/Survival, de Novo HLA Antibodies Development
Interventions
Rituximab plus immunosuppression, Placebo plus immunosuppression
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 70 Years
Enrollment
757 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
17
States / cities
Birmingham, Alabama • San Francisco, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2015 · Synced Sep 22, 2026, 1:58 AM EDT
Completed Phase 2 Interventional Results available

A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection

NCT01147302
View directory record Official record
Conditions
Graft Rejection
Interventions
Placebo, C1 Esterase Inhibitor (Human)
Biological
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 22, 2026, 1:58 AM EDT
Recruiting Not applicable Interventional

Cryoprobe Biopsy and Chronic Rejection in Lung Transplant Recipients

NCT06824402
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
Forceps Biopsy, Cryoprobe Biopsy
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 22, 2026, 1:58 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients

NCT01650545
View directory record Official record
Conditions
Disorder Related to Lung Transplantation, Bronchiolitis Obliterans, Decreased Immunologic Activity, Chronic Rejection of Lung Transplant
Interventions
Liposomal aerosol cyclosporine, standard immune suppression, oral
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Sep 22, 2026, 1:58 AM EDT
Completed Phase 3 Interventional Results available

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)

NCT03656926
View directory record Official record
Conditions
Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
Interventions
Liposomal Cyclosporine A, Standard of Care
Drug
Lead sponsor
Zambon SpA
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
21
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 22, 2026, 1:58 AM EDT
Withdrawn Phase 4 Interventional

Macitentan in the Treatment of Organ Rejection After Lung Transplantation

NCT02893176
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
macitentan, placebo (for macitentan)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Sep 22, 2026, 1:58 AM EDT
Completed Phase 4 Interventional

A Study to Compare the Conversion to Prograf® (Tacrolimus) to the Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure

NCT00510913
View directory record Official record
Conditions
Graft Rejection, Kidney Transplantation
Interventions
tacrolimus
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
12 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
18
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2007 · Synced Sep 22, 2026, 1:58 AM EDT
Withdrawn Phase 2 Interventional

Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD

NCT02563782
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Sub-retinal transplantation of MA09-hRPE cells, tacrolimus and mycophenolate mofetil, Placebo tacrolimus and mycophenolate mofetil, Sham Surgery
Biological · Drug · Procedure
Lead sponsor
Astellas Institute for Regenerative Medicine
Industry
Eligibility
50 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Sep 22, 2026, 1:58 AM EDT
Active, not recruiting Phase 2 Interventional

BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)

NCT05156710
View directory record Official record
Conditions
Transplant Rejection
Interventions
BIVV020 (SAR445088), Intravenous immunoglobulin (IVIg), Rituximab or biosimilar, Antithymocyte globulin (ATG), Tacrolimus, Mycophenolate, Corticosteroids
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 22, 2026, 1:58 AM EDT
Completed No phase listed Observational

Longitudinal Study of Cell Free DNA in Lung Transplant

NCT04234919
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Sep 22, 2026, 1:58 AM EDT
Recruiting No phase listed Observational

Trifecta-Kidney cfDNA-MMDx Study

NCT04239703
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
MMDx, Prospera, HLA antibody
Diagnostic Test
Lead sponsor
University of Alberta
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
11
States / cities
Tampa, Florida • Baltimore, Maryland • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 22, 2026, 1:58 AM EDT
Completed Phase 2 Interventional

An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.

NCT00235300
View directory record Official record
Conditions
Cadaveric Donor Renal Transplantation, Acute Renal Allograft Rejection, Induction Therapy
Interventions
Thymoglobulin [Anti-thymocyte Globulin (rabbit)], Simulect (basliximab)
Biological · Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Sep 22, 2026, 1:58 AM EDT
Recruiting Not applicable Interventional

Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients

NCT05732779
View directory record Official record
Conditions
Heart Transplant Rejection, Immune Suppression, Pediatric Heart Transplant, Medication Nonadherence, Health Behavior, Remote Monitoring, Patient Engagement
Interventions
DOT intervention
Other
Lead sponsor
University of Florida
Other
Eligibility
10 Years to 21 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Coral Gables, Florida • Gainesville, Florida • Hollywood, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 22, 2026, 1:58 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients

NCT01544491
View directory record Official record
Conditions
Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant
Interventions
RAD001, MMF
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 18 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Ann Arbor, Michigan • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Sep 22, 2026, 1:58 AM EDT
Not listed No phase listed Observational

TruGraf® Long-term Clinical Outcomes Study

NCT04491552
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Patients monitored with TruGraf and TRAC testing
Diagnostic Test
Lead sponsor
Transplant Genomics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
36
States / cities
Tucson, Arizona • Fresno, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Sep 22, 2026, 1:58 AM EDT
Completed No phase listed Observational Results available

The Differential Effects of 3 Different Immunosuppressive

NCT00729248
View directory record Official record
Conditions
Immunosuppression, Kidney Transplantation
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Sep 22, 2026, 1:58 AM EDT
Active, not recruiting No phase listed Observational

Surveillance HeartCare® Outcomes Registry

NCT03695601
View directory record Official record
Conditions
Heart Transplant Rejection
Interventions
Standard of Care
Other
Lead sponsor
CareDx
Industry
Eligibility
15 Years and older
Enrollment
2,743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
67
States / cities
Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 22, 2026, 1:58 AM EDT